koko体育app

Abstract: Objective To analysis the clinical characterist ics of children with cough variation asthma （CVA） who received treatments with Carboxymethl starch sodium solution and inhaled Glucocorticoid budesonide． Methods A total of 96 children with CVA were divided into two g rou p randomly. The control group (n=49) received inhaled budesonide treatment ( 500 μg/times in 1-5 years old children, 1 mg/times and 2 times/day in 6-14 ye a rs old children over a 12 week period). The children in treatment group (n=4 7) were given carboxymethl starch sodium solution (3 mL/times in 1-3 years old children, 5 mL/times in 4-7 years old children, 7 mL/times in 8-14 years old c hildren, 3 times/day) in addition to the inhaled budesonide treatment. Observati ons were made on clinical therapeutic effects, cough score and the level of IgE 4 weeks, 8 weeks and 12 weeks after the treatments, respectively. Recurrence rat e and adv erse reactions were investigated. Results Compared with the con trol group, the treatment group had significantly improved clinical characterist ics after 8 weeks and 12 weeks of treatments (P<0.05), and reduced cough sco res after 4 weeks, 8 weeks and 12 weeks of treatments (P<0.05). The IgE leve l of the children in the treatment group was significantly lower than the contro ls after 12 weeks of treatments (P<0.05). The treatment group also had significantly lower recurrence rate and adverse reactions than the controls ( P<0.05)．Conclusion Carboxymethl starch sodium solution can boost the clinical efficiency of inhaled budesonide in the treatment of childre n with cough variant asthma. It is safe and effectual.